Limula, a Swiss life sciences tools company advancing automated solutions for cell and gene therapy (CGT) manufacturing, has successfully installed its first LimONE device at Stemmatters, a boutique contract development and manufacturing organization (CDMO) based in Portugal and specialised in advanced therapies.
This delivery represents a major milestone in both Limula’s product development journey and the completion of the PAT4CGT project aimed at accelerating the development of personalized advanced therapies, towards broader patient accessibility.
LimONE is a fully integrated, closed-system platform that automates all critical steps in the CGT manufacturing workflow. Its design significantly reduces manual interventions and contamination risk, improving process reliability and consistency, increasing product quality. By consolidating all critical steps into one device, LimONE enhances throughput by lowering equipment, consumable and infrastructure costs, while its scalable architecture supports seamless transition from early-stage development to clinical-grade and commercial manufacturing.
Limula and Stemmatters have been collaborating closely for over three years, with Stemmatters actively contributing design inputs and feedback throughout LimONE’s product development. This partnership has taken a Quality by Design approach instrumental in ensuring the device, consumable and software meet real-world manufacturing needs, towards readiness for GMP environments.
